A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer

Trial ID or NCT#

NCT01876251

Status

not recruiting iconNOT RECRUITING

Purpose

This study is aimed to determine the tolerability of the PF-03084014 plus docetaxel combination in patients with advanced breast cancer. Preliminary information about the efficacy of the combination will also be collected.

Official Title

Phase 1b Study Of Docetaxel + Pf 03084014 In Metastatic Or Locally Recurrent/Advanced Triple Negative Breast Cancer

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: Female
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Diagnosis of breast cancer with evidence of a) metastatic or b) locally recurrent/advanced disease.
Exclusion Criteria:
  1. - Prior treatment with a gamma secretase inhibitors or other Notch signaling inhibitors.

Investigator(s)

Mark Pegram
Medical oncologist, Breast specialist
Susy Yuan-Huey Hung Professor
Allison W. Kurian, M.D., M.Sc.
Allison W. Kurian, M.D., M.Sc.
Medical oncologist, Breast specialist, Cancer geneticist
Professor of Medicine (Oncology) and of Epidemiology and Population Health

Contact us to find out if this trial is right for you.

CONTACT

CCTO
(650) 498-7061